IFIH1 and dermatomyositis: In 2022, Coutant et al.9analyzed the serum samples of 29 anti‐MDA5 dermatomyositis (DM) patients by indirect immunofluorescence on Hep‐2 cells, to identify patterns associated with poor outcome.